Other Clinical Trial - First in Human Study of M1069 in Advanced Solid

See also
Status	Clinical Trial	Phase
Terminated	`NCT03306420` - First-in-Human Study of MS201408-0005A as Single Agent and in Combinations	Phase 1
Recruiting	`NCT05396833` - Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320)	Phase 1
Active, not recruiting	`NCT04170153` - Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)	Phase 1

See also

Status

Clinical Trial

Phase

Terminated

NCT03306420 - First-in-Human Study of MS201408-0005A as Single Agent and in Combinations

Phase 1

Recruiting

NCT05396833 - Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320)

Phase 1

Active, not recruiting

NCT04170153 - Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)

Phase 1

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT05198349
Study type	Interventional
Source	EMD Serono
Contact
Status	Terminated
Phase	Phase 1
Start date	March 2, 2022
Completion date	August 10, 2023

First in Human Study of M1069 in Advanced Solid Tumors

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms